• Explore /
  • Poster
  • / Secondary efficacy subanalysis by histology from the phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL).

Secondary efficacy subanalysis by histology from the phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL).

Abstract Poster

Authors

Ian Flinn

Ian Flinn

Sarah Cannon Research Institute, Nashville, TN

Ian Flinn , Richard H. C. Van Der Jagt , Brad S. Kahl , Peter Wood , Tim E. Hawkins , David MacDonald , Mark Hertzberg , Yiu-Lam Kwan , David Simpson , Michael Craig , Kathryn S. Kolibaba , Samar Issa , Regina Clementi , Doreen M. Hallman , Mihaela C. Munteanu , Ling Chen , John M. Burke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Clinical Trial Registration Number

NCT00877006

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8537)

DOI

10.1200/jco.2013.31.15_suppl.8537

Abstract #

8537

Poster Bd #

17

Abstract Disclosures

Similar Posters

First Author: David MacDonald

First Author: Yucai Wang

First Author: Helena Alexandra Yu

First Author: Ruemu Ejedafeta Birhiray